Covered recipient · General Payments record
YULIYA PL LINHARES
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$123,682.47
- Reported across 174 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,800.00 | 5 |
| Food and Beverage | $1,052.14 | 17 |
| Travel and Lodging | $643.89 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Kite Pharma, Inc. | $7,971.73 | 4 |
| Genmab U.S., Inc. | $3,124.44 | 13 |
| Acerta Pharma LLC | $2,740.00 | 1 |
| Kyowa Kirin, Inc. | $2,350.89 | 3 |
| GENZYME CORPORATION | $247.72 | 3 |
| BeiGene USA, Inc. | $32.56 | 1 |
| Daiichi Sankyo Inc. | $28.69 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (26)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,740.00 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105558562 | CMS |
| BeiGene USA, Inc. | $32.56 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120860987 | CMS |
| Daiichi Sankyo Inc. | $28.69 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089449216 | CMS |
| Genmab U.S., Inc. | $152.96 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833564 | CMS |
| Genmab U.S., Inc. | $50.35 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833588 | CMS |
| Genmab U.S., Inc. | $388.96 | 10/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126833566 | CMS |
| Genmab U.S., Inc. | $7.65 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833568 | CMS |
| Genmab U.S., Inc. | $210.15 | 11/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126833570 | CMS |
| Genmab U.S., Inc. | $7.65 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833574 | CMS |
| Genmab U.S., Inc. | $29.78 | 11/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126833576 | CMS |
| Genmab U.S., Inc. | $70.36 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833578 | CMS |
| Genmab U.S., Inc. | $28.19 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833582 | CMS |
| Genmab U.S., Inc. | $55.20 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833584 | CMS |
| Genmab U.S., Inc. | $28.19 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126833586 | CMS |
| Genmab U.S., Inc. | $15.00 | 11/09/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126833572 | CMS |
| Genmab U.S., Inc. | $2,080.00 | 12/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1126833580 | CMS |
| GENZYME CORPORATION | $21.86 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139681887 | CMS |
| GENZYME CORPORATION | $99.89 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139681929 | CMS |
| GENZYME CORPORATION | $125.97 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139681947 | CMS |
| Kite Pharma, Inc. | $4,630.00 | 01/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1128611145 | CMS |
| Kite Pharma, Inc. | $13.04 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128611149 | CMS |
| Kite Pharma, Inc. | $108.69 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128611151 | CMS |
| Kite Pharma, Inc. | $3,220.00 | 09/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1128611147 | CMS |
| Kyowa Kirin, Inc. | $141.38 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127045815 | CMS |
| Kyowa Kirin, Inc. | $2,130.00 | 08/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1127045817 | CMS |
| Kyowa Kirin, Inc. | $79.51 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127045819 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.